Re­gen­eron scores Eylea patent win against My­lan, keep­ing biosim­i­lar at bay

Re­gen­eron pre­vailed in a ma­jor patent fight against My­lan, staving off biosim­i­lar com­pe­ti­tion for its flag­ship eye drug Eylea for an­oth­er few years.

The big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.